The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Last month however saw the approval of its first direct competitor – Sanofi’s anti-CD38 antibody Sarclisa (isatuximab) – which was given the nod by the FDA as a third-line therapy for myeloma.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson ... as a first-line therapy for blood cancer multiple myeloma as a combination regimen alongside bortezomib ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

Panelists discuss how the PERSEUS trial demonstrated superior progression-free survival with daratumumab-VRd compared to VRd alone in patients with transplant-eligible newly diagnosed multiple myeloma ...

The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab ... Its products include daratumumab to treat MM, non-MM blood ...

Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...